Iradimed (NASDAQ:IRMD) updated its FY18 earnings guidance on Tuesday. The company provided EPS guidance of $0.33-$0.38 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.35. The company issued revenue guidance of $29.3-$30.0 million, compared to the consensus revenue estimate of $29.70 million.Iradimed also updated its Q1 guidance to $0.06-$0.07 EPS.

IRMD has been the subject of several analyst reports. Credit Suisse Group initiated coverage on Iradimed in a report on Monday, November 27th. They issued a buy rating and a $19.00 price target for the company. Roth Capital initiated coverage on Iradimed in a report on Tuesday, October 31st. They issued a buy rating and a $16.00 price target for the company. Finally, Zacks Investment Research upgraded Iradimed from a hold rating to a buy rating and set a $17.00 price target for the company in a report on Friday, January 26th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $17.33.

Iradimed (NASDAQ IRMD) opened at $14.50 on Wednesday. The firm has a market capitalization of $158.86, a price-to-earnings ratio of 111.55 and a beta of 1.45. Iradimed has a twelve month low of $7.85 and a twelve month high of $15.85.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 6th. The medical equipment provider reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.08. The company had revenue of $6.70 million during the quarter, compared to the consensus estimate of $6.72 million. Iradimed had a return on equity of 4.58% and a net margin of 6.51%. Iradimed’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.11 EPS. research analysts expect that Iradimed will post 0.05 EPS for the current year.

In other Iradimed news, Director Monty K. Allen sold 1,898 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.95, for a total value of $26,477.10. Following the completion of the transaction, the director now directly owns 9,062 shares in the company, valued at approximately $126,414.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 60.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Iradimed (IRMD) Issues FY18 Earnings Guidance” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/02/07/iradimed-irmd-issues-fy18-earnings-guidance.html.

About Iradimed

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.